Skip to main content
Premium Trial:

Request an Annual Quote

MRC Holland Gets CE-IVD Mark for Spinal Muscular Atrophy Assay

NEW YORK (GenomeWeb) — Dutch biotech firm MRC Holland said recently that it has received CE-IVD marking for its SALSA MC002 assay for spinal muscular atrophy (SMA) screening in newborns. It added it has launched the test.

SMA is a neuromuscular disease caused by mutations in the SMN1 gene. According to MRC Holland, the melt curve analysis-based assay is designed to detect the presence or absence of SMN1 exon 7 in newborns. It does not require DNA purification and can provide results from dried blood spot card punches in around four hours.

MRC Holland noted that the market for SMA screening has increased with the 2016 approval of Biogen Idec's treatment Spinraza (nusinersen), which is administered before symptoms appear.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.